1. Home
  2. ELE vs PHAR Comparison

ELE vs PHAR Comparison

Compare ELE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elemental Royalty Corporation

ELE

Elemental Royalty Corporation

N/A

Current Price

$21.29

Market Cap

1.0B

Sector

N/A

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$11.15

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELE
PHAR
Founded
N/A
1988
Country
Canada
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
ELE
PHAR
Price
$21.29
$11.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$32.50
$38.33
AVG Volume (30 Days)
274.1K
21.9K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
0.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$109.25
$10.04
Revenue Next Year
$16.14
$2.51
P/E Ratio
$255.64
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$14.01
$9.62
52 Week High
$26.96
$21.34

Technical Indicators

Market Signals
Indicator
ELE
PHAR
Relative Strength Index (RSI) 59.89 44.74
Support Level $20.87 $9.62
Resistance Level $22.45 $13.51
Average True Range (ATR) 0.78 0.35
MACD -0.22 -0.00
Stochastic Oscillator 47.86 27.18

Price Performance

Historical Comparison
ELE
PHAR

About ELE Elemental Royalty Corporation

Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments. It is the result of the strategic merger of Elemental Altus Royalties and EMX Royalty Corporation together creating a mid-tier gold-focused royalty company with the scale, diversification, and cash flow. Geographically, the company generates revenue from North America, South America, Europe, Australia and Africa.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: